A detailed history of Ubs Oconnor LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 30,000 shares of NBIX stock, worth $4.1 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
30,000
Holding current value
$4.1 Million
% of portfolio
0.24%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$114.58 - $153.15 $1.76 Million - $2.35 Million
15,370 Added 94.29%
31,670 $3.65 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $300,978 - $329,337
2,300 Added 16.43%
16,300 $2.24 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $755,798 - $833,117
-5,796 Reduced 29.28%
14,000 $1.93 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $1.49 Million - $1.86 Million
-14,002 Reduced 41.43%
19,796 $2.61 Million
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $470,100 - $585,500
-5,000 Reduced 12.89%
33,798 $3.8 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $3.47 Million - $4.07 Million
38,798 New
38,798 $3.66 Billion
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $2.38 Million - $3.11 Million
25,242 Added 424.95%
31,182 $3.16 Million
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $1.18 Million - $1.41 Million
-11,063 Reduced 65.06%
5,940 $0
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $1.86 Million - $2.18 Million
-20,200 Reduced 54.3%
17,003 $1.81 Billion
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $924,865 - $1.22 Million
12,203 Added 48.81%
37,203 $3.63 Million
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $1.81 Million - $2.37 Million
25,000 New
25,000 $2.34 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.